Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation of selective epoxide hydrolase II inhibitor

A cyclooxygenase and inhibitor technology, applied in the field of new pharmaceutical preparations, can solve problems such as the inability to provide cyclooxygenase 2 inhibitors

Inactive Publication Date: 2005-01-05
迪内希·尚蒂拉尔·帕特尔 +2
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Therefore, because of the above-mentioned solubility and toxicity problems, the prior art cannot provide cyclooxygenase 2 inhibitors that can be administered directly by injection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation of selective epoxide hydrolase II inhibitor
  • Preparation of selective epoxide hydrolase II inhibitor
  • Preparation of selective epoxide hydrolase II inhibitor

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0049] While stirring, 3.976 mmol of rofecoxib was added to 100 ml of 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol. The solution was stirred for an additional 15 minutes under aseptic conditions. The sterile-filtered solution is sealed in vials / ampoules.

example 2

[0051] While stirring, 3.976 mmol of rofecoxib was added to 80 ml of 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol. Continue to stir the solution under aseptic conditions and add 20ml of water for injection. The solution (diluted to 100 ml with 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol) was sterile filtered and sealed into vials / ampoules.

example 3

[0053] While stirring, 7.952 mmol of rofecoxib was added to 80 ml of 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol. The solution was continuously stirred under aseptic conditions and 20ml of water for injection was added. The solution (diluted to 100 ml with 2,5-bis-O-methyl-1,4:3,6 dianhydro-D-glucitol) was sterile filtered and sealed into vials / ampoules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A transparent stable injection preparation of a new selective epoxide hydrolase II(cyclooxygenase II) inhibitor, is used for the treatment of pain and the inflammation that causes by cyclooxygenase II, especially the preparation is prepared by dissolving the selective active cyclooxygenase II inhibitor such as cyclooxygenase II inhibitor selected from example choose from celebrex, vioxx and their homologous compounds, into solvent such as isobide ester isosorbide as shown by the chemical formula I, wherein, R[1] and R[2] are hydrogen atom or the alkyl or acetic acid ester of 1 - 3 carbons; also disclosed is a simple and cost-rational preparation method of tha said new medicine preparation.

Description

Technical field: [0001] The invention relates to a novel pharmaceutical preparation of a transparent and stable selective cyclooxygenase 2 (CYCLOOXY GE NASEII, abbreviated as COX2) inhibitor, which is suitable for injection to treat pain and inflammation symptoms caused by cyclooxygenase 2. Background technique: [0002] Selective cyclooxygenase 2 inhibitors such as Celecoxib, Rofecoxib and their homologues are widely used to treat musculoskeletal disorders such as rheumatoid arthritis, bone Osteoarthritis, ankylosing spondylitis, and acute pain. They are also used as the medicine of choice for dysmenorrhea. Long-term treatment with celecoxib and rofecoxib can effectively suppress inflammation without the gastric toxicity of conventional non-selective non-steroidal anti-inflammatory drugs (NSAIDs) (Simon et al., 1998, 1999; Bensen et al., 1999; Emery et al. 1999; Howaky et al. 2000; Schintzer et al. 1999; Ehlidrich et al. 1999; Laine et al. 1999 through Goodman & Gilman's ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K31/415A61K31/42A61K47/26
Inventor 迪内希尚蒂拉尔·帕特尔萨钦迪内希·帕特尔沙希坎特普拉布达斯·库拉尼
Owner 迪内希·尚蒂拉尔·帕特尔
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com